M. Michael

876 total citations
14 papers, 699 citations indexed

About

M. Michael is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, M. Michael has authored 14 papers receiving a total of 699 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in M. Michael's work include Colorectal Cancer Treatments and Studies (6 papers), Gastric Cancer Management and Outcomes (4 papers) and Colorectal and Anal Carcinomas (3 papers). M. Michael is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Gastric Cancer Management and Outcomes (4 papers) and Colorectal and Anal Carcinomas (3 papers). M. Michael collaborates with scholars based in Australia, Spain and United Kingdom. M. Michael's co-authors include Scott Berry, David Cunningham, M. Mazier, Maria Di Bartolomeo, Fernando Rivera, Albrecht Kretzschmar, Eric Van Cutsem, John Bridgewater, Marc Peeters and Vassilis Georgoulias and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

M. Michael

14 papers receiving 681 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Michael Australia 9 590 238 203 153 74 14 699
Georgios Karagkounis United States 16 627 1.1× 177 0.7× 294 1.4× 310 2.0× 61 0.8× 45 841
Farid Fata United States 10 584 1.0× 391 1.6× 123 0.6× 124 0.8× 37 0.5× 15 779
B-Y. Ryoo South Korea 9 313 0.5× 332 1.4× 153 0.8× 166 1.1× 66 0.9× 36 581
Woo Kun Kim South Korea 13 376 0.6× 242 1.0× 78 0.4× 107 0.7× 180 2.4× 36 643
Selenia Casnedi France 9 612 1.0× 116 0.5× 358 1.8× 337 2.2× 233 3.1× 18 773
Anwar Giryes Switzerland 12 374 0.6× 180 0.8× 78 0.4× 133 0.9× 133 1.8× 21 602
J. Wals Netherlands 8 537 0.9× 176 0.7× 153 0.8× 102 0.7× 20 0.3× 15 664
Naofumi Eriguchi Japan 16 324 0.5× 216 0.9× 197 1.0× 385 2.5× 201 2.7× 60 716
Su Jung Shim South Korea 14 294 0.5× 156 0.7× 228 1.1× 303 2.0× 75 1.0× 34 819
Clemens Gießen-Jung Germany 11 499 0.8× 193 0.8× 115 0.6× 118 0.8× 22 0.3× 34 687

Countries citing papers authored by M. Michael

Since Specialization
Citations

This map shows the geographic impact of M. Michael's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Michael with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Michael more than expected).

Fields of papers citing papers by M. Michael

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Michael. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Michael. The network helps show where M. Michael may publish in the future.

Co-authorship network of co-authors of M. Michael

This figure shows the co-authorship network connecting the top 25 collaborators of M. Michael. A scholar is included among the top collaborators of M. Michael based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Michael. M. Michael is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
1.
2.
Martin, Jennifer, Lisa Orme, Beatrice Seddon, et al.. (2018). Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood. Cancer Chemotherapy and Pharmacology. 82(5). 887–898. 12 indexed citations
3.
Kong, Joseph C., Glen Guerra, Satish K. Warrier, et al.. (2018). Prognostic value of tumour regression grade in locally advanced rectal cancer: a systematic review and meta‐analysis. Colorectal Disease. 20(7). 574–585. 51 indexed citations
4.
Czito, Brian G., Mary F. Mulcahy, Dustin A. Deming, et al.. (2015). Safety and Tolerability of Veliparib Combined With Capecitabine Plus Radiation Therapy in Patients With Locally Advanced Rectal Cancer: Final Results of a Phase 1b Study. International Journal of Radiation Oncology*Biology*Physics. 93(3). S206–S206. 1 indexed citations
5.
Kong, Grace, Matthew Thompson, Marnie Collins, et al.. (2014). Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT). European Journal of Nuclear Medicine and Molecular Imaging. 41(10). 1831–1844. 70 indexed citations
6.
Czito, Brian G., Mary F. Mulcahy, William R. Schelman, et al.. (2014). The Safety and Tolerability of Veliparib (V) plus Capecitabine (C) and Radiation (RT) in Subjects with Locally Advanced Rectal Cancer (LARC): Results of a Phase 1b Study. International Journal of Radiation Oncology*Biology*Physics. 90(1). S22–S22. 2 indexed citations
7.
Cutsem, Eric Van, Fernando Rivera, Scott Berry, et al.. (2009). Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Annals of Oncology. 20(11). 1842–1847. 423 indexed citations
8.
Cutsem, Eric Van, Francisca Rivera, Scott Berry, et al.. (2009). 6088 Safety and efficacy of bevacizumab (BEV) and chemotherapy in elderly patients with metastatic colorectal cancer (mCRC): results from the BEAT observational cohort study. European Journal of Cancer Supplements. 7(2). 349–349. 6 indexed citations
9.
Kretzschmar, Albrecht, Eric Van Cutsem, M. Michael, et al.. (2007). Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI and monotherapy for mCRC: First BEATrial. Journal of Clinical Oncology. 25(18_suppl). 4072–4072. 14 indexed citations
10.
Berry, Scott, David Cunningham, M. Michael, et al.. (2006). Preliminary safety of bevacizumab with first-line Folfox, Capox, Folfiri and capecitabine for mCRC—First B.E.A.Trial. Journal of Clinical Oncology. 24(18_suppl). 3534–3534. 40 indexed citations
11.
Michael, M., A. Kretzschmar, Scott Berry, et al.. (2006). Feasibility of metastasectomy in patients treated with bevacizumab in first-line mCRC - Preliminary results from the First Beat-study. Journal of Clinical Oncology. 24(18_suppl). 3523–3523. 10 indexed citations
12.
Michael, M., Philip B. Mitchell, Rodney J. Hicks, et al.. (2004). The utility of in-vivo functional and genetic parameters of drug elimination for the estimation of irinotecan (Ir) clearance (CL). Journal of Clinical Oncology. 22(14_suppl). 2034–2034. 2 indexed citations
13.
Michael, M., Paul Mitchell, Rodney J. Hicks, et al.. (2004). The utility of in-vivo functional and genetic parameters of drug elimination for the estimation of irinotecan (Ir) clearance (CL). Journal of Clinical Oncology. 22(14_suppl). 2034–2034. 1 indexed citations
14.
Solomon, Benjamin, David Ball, Gary Richardson, et al.. (2003). Phase I/II study of concurrent twice-weekly paclitaxel and weekly cisplatin with radiation therapy for stage III non-small cell lung cancer. Lung Cancer. 41(3). 353–361. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Georgios Karagkounis Breakdown of academic impact, for papers by Farid Fata Breakdown of academic impact, for papers by B-Y. Ryoo Breakdown of academic impact, for papers by Woo Kun Kim Breakdown of academic impact, for papers by Selenia Casnedi Breakdown of academic impact, for papers by Anwar Giryes Breakdown of academic impact, for papers by J. Wals Breakdown of academic impact, for papers by Naofumi Eriguchi Breakdown of academic impact, for papers by Su Jung Shim Breakdown of academic impact, for papers by Clemens Gießen-Jung
Rankless by CCL
2026